DISCLAIMER
The information and materials accessed through or made available for use on any of our Sites, including, any information about diseases, conditions, treatments, or medicines, are for informational purposes only. The Content is not intended to be and is not a substitute for professional medical advice, diagnosis, or treatment, and your participation on our Sites does not create a healthcare professional-patient relationship. You should consult a doctor or other qualified health care professional regarding any questions you have about your health or before making any decisions related to your health or wellness. Call your doctor or 911 immediately if you think you may have a medical emergency.compose your message
message sent
email sent successfully
Trusted Resources: News & Events
Latest announcements and gatherings
FDA grants CRISPR gene therapy fast track designation for sickle cell disease
The FDA granted fast track designation to CTX001, a gene-edited hematopoietic stem cell therapy, for the treatment of sickle cell disease.
CTX001 (CRISPR Therapeutics, Vertex Pharmaceuticals Inc.) is an investigational, autologous gene therapy under evaluation for patients with severe hemoglobinopathies. The ex-vivo therapy involves engineering a patient’s hematopoietic stem cells to produce high levels of fetal hemoglobin in red blood cells, with the goal of alleviating transfusion requirements for patients with beta-thalassemia and sickle crises for patients with sickle cell disease.
Related Content
-
news & eventsSickle Cell Patient Receives CRISPR Gene TherapyMany human diseases can be traced back t...
-
news & eventsProdigy’s death shines light on slow progress against sickle cell diseaseThe death of the rap artist Prodigy (Alb...
-
news & eventsSickle-Cell Patients See Hope in CRISPRSickle-cell disease is one of the most c...
-
education & researchGene Therapy: What You Need to Know (Warrior FAQs)Two gene therapies were recently approve...
-
Community CenterSickle Cell Disease: Gene-Editing Tools Point to Possible Ultimate CureRecent advances in CRISPR/Cas9 gene-edit...
-
news & eventsMaxCyte, Inc. to Present Positive Preclinical Data for Sickle Cell DiseaseMaxCyte, a US-based global company dedic...
-
news & eventsProgress in pursuit of sickle cell cureBao, in collaboration with Baylor Colleg...
send a message
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.